Specialty Pharmacy was Starling Oncology’s largest product and service line in fiscal 2025, bringing in $807.53M of $1.51B (54%).
| Product and Service | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Specialty Pharmacy | — | — | $539.75M | $807.53M | ||
| Ffs Revenue | $316.33M | $429.40M | $408.59M | $445.53M | ||
| Dispensary | $238.03M | $311.51M | — | — | ||
| Capitated Revenue | $184.02M | $211.11M | $206.06M | $241.44M | ||
| Clinical Trials Other | $19.07M | $20.70M | $25.84M | $13.69M | ||
| Total | $757.45M | $972.72M | $1.18B | $1.51B |
Starling Oncology brought in $1.51B from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 27.8% from $1.18B in fiscal 2024. Specialty Pharmacy was the largest at $807.53M (53.5%), ahead of Ffs Revenue at $445.53M (29.5%) and Capitated Revenue at $241.44M (16.0%). The remaining line, Clinical Trials Other, brought in $13.69M.
Compared with fiscal 2024, Specialty Pharmacy grew fastest, up 49.6% to $807.53M. Every line above 2% of revenue grew.
Starling Oncology began breaking out Specialty Pharmacy in fiscal 2024, when it brought in $539.75M. Starling Oncology stopped reporting Dispensary as a separate line after fiscal 2023, when it brought in $311.51M.
Specialty Pharmacy was Starling Oncology’s largest segment in fiscal 2025, bringing in $807.53M of $1.51B (54%).
| Segment | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Specialty Pharmacy | — | — | $539.75M | $807.53M | ||
| Patient Services | $500.36M | $640.51M | $614.65M | $686.97M | ||
| Dispensary | $238.03M | $311.51M | — | — | ||
| Clinical Trials Other | $19.07M | $20.70M | $25.84M | $13.69M | ||
| Total | $757.45M | $972.72M | $1.18B | $1.51B |
Starling Oncology brought in $1.51B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 27.8% from $1.18B in fiscal 2024. Specialty Pharmacy was the largest at $807.53M (53.5%), ahead of Patient Services at $686.97M (45.5%) and Clinical Trials Other at $13.69M (0.9%).
Compared with fiscal 2024, Specialty Pharmacy grew 49.6% to $807.53M and Patient Services grew 11.8% to $686.97M.
Starling Oncology began breaking out Specialty Pharmacy in fiscal 2024, when it brought in $539.75M. Starling Oncology stopped reporting Dispensary as a separate segment after fiscal 2023, when it brought in $311.51M.
Starling Oncology (STLN) reports its revenue by product and service and by segment. In fiscal 2025, Specialty Pharmacy was its largest product and service line, bringing in $807.53M (53.5% of the total), followed by Ffs Revenue at $445.53M (29.5%).
Specialty Pharmacy was Starling Oncology's largest product and service line in fiscal 2025, bringing in $807.53M, or 53.5% of the $1.51B total across its four product and service lines.
Specialty Pharmacy was Starling Oncology's largest segment in fiscal 2025, bringing in $807.53M, or 53.5% of the $1.51B total across its three segments.
Among Starling Oncology's product and service lines that make up at least 2% of revenue, Specialty Pharmacy grew fastest in fiscal 2025, up 49.6% from $539.75M to $807.53M.
Every figure comes from Starling Oncology's annual financial filings, as reported. Each line keeps the name Starling Oncology gives it, and years follow its fiscal calendar.
Starling Oncology's revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.